The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis

Published:2020-02 Issue: Volume:38 Page:101514
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Petruzzo Martina,Palladino Raffaele^ORCID,Nardone Antonio,Nozzolillo Agostino,Servillo Giuseppe,Orlando Valentina,De Angelis Marcello,Lanzillo Roberta^ORCID,Brescia Morra Vincenzo,Moccia Marcello^ORCID

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference51 articles.

1. Agenzia Italiana del Farmaco, 2019. Banca Dati Farmaci dell'AIFA [WWW Document]. URLhttps://www.farmaci.agenziafarmaco.gov.it/(accessed 9.18.19).

2. Bank of Italy, n.d. Euro foreign exchange reference rates as of 5 Apr 2019 [WWW Document]. URLhttps://www.bancaditalia.it/compiti/operazioni-cambi/cambio/cambi_rif_20190405/(accessed 4.5.19).

3. Quasi-experimental study designs series—paper 4: uses and value;Bärnighausen;J. Clin. Epidemiol.,2017

4. New insights into the burden and costs of multiple sclerosis in Europe: Results for italy;Battaglia;Mult. Scler.,2017

5. Interrupted time series regression for the evaluation of public health interventions: a tutorial;Bernal;Int. J. Epidemiol.,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A place for biosimilars in the changing multiple sclerosis treatment landscape;Multiple Sclerosis and Related Disorders;2023-09

2. A Global, Regional, and National Survey on Burden and Quality of Care Index of Multiple Sclerosis: Global Burden of Disease Systematic Analysis 1990–2019;Neuroepidemiology;2023

3. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany;Neurodegenerative Disease Management;2021-12-21

4. Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database;Expert Review of Pharmacoeconomics & Outcomes Research;2021-07-08

5. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA;Current Neurology and Neuroscience Reports;2021-05-05